EMB 09
Alternative Names: EMB-09Latest Information Update: 02 Nov 2023
At a glance
- Originator EpimAb Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; OX40 receptor agonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 02 Mar 2022 EpimAb Biotherapeutics plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in April 2022 (IV) (NCT05263180)
- 30 Jul 2021 EMB 09 is available for licensing as of 30 Jul 2021. (EpimAB Biotherapeutics, July 2021)
- 30 Jul 2021 Preclinical trials in Solid tumours in China (Parenteral) prior to July 2021 (EpimAB Biotherapeutics, July 2021)